CTIS2023-509061-20-00进行中（未招募）1 期
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers - CA027-002
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 639
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •At least 1 lesion accessible for biopsy, Eastern Cooperative Oncology Group Performance Status of 0 or 1, Non-small cell lung carcinoma (only Part 1A and Part 1 Cohorts 1B1 through 1B5 [enrolled through revised Protocol 03]. Participants with NSCLC will not be allowed in Parts 1B6, 1B7 and 1C as per protocol Amendment 04).
排除标准
- •Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll), Participants with active, known or suspected autoimmune disease, Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration, Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS), Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
研究者
相似试验
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersEUCTR2018-000340-26-DEBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersAdvanced CancersMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000340-26-PLBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersEUCTR2018-000340-26-BEBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-GBBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO800